# Macitentan

Drug · id `cardio:macitentan` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

Also called: OPSUMIT

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

Macitentan, sold as Opsumit, is an endothelin receptor antagonist. The US label lists treating pulmonary arterial hypertension (WHO Group I) in adults, to reduce the risks of disease progression and hospitalization for pulmonary arterial hypertension. The label carries a boxed warning for embryo-fetal toxicity: it says the medicine is contraindicated during pregnancy because it may cause fetal harm. That risk concerns the unborn child and is recorded separately.

## Technical summary

RxNorm ingredient 1442132; UNII Z9K9Y9WMVL. MeSH has no descriptor for macitentan (an exact-label lookup returned an empty list on 2026-11-18), so the record carries no MeSH code. RxClass lists the FDA established pharmacologic class Endothelin Receptor Antagonist, so the record is filed under the class page. The label read is the Actelion Pharmaceuticals US, Inc. label for Opsumit, application NDA204410 (approved 2013-10-18 as a new molecular entity in Drugs@FDA), effective 2025-04-11 in openFDA. A combination product of macitentan and tadalafil (Opsynvi, NDA218490) is a separate product and was not read. The adult indication and the boxed warning (recipient: fetal) sit in separate claims and contexts. This page records the label indication, the boxed-warning title and one sentence, the mechanism sentence and the class only: no trial result and no dose is given.

## Claims, with the population each applies to

## Context: The developing fetus, for a person taking macitentan during pregnancy, as described in a US label boxed warning

Recipient: Fetal; Population: The developing fetus when a pregnant person takes the medicine, as the label boxed warning describes the risk. The warning is not about the person who takes the medicine.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Fetus during pregnancy; the passage read gives no gestational ages; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)

### The same US label of Opsumit carries a boxed warning titled embryo-fetal toxicity. It says the medicine is contraindicated for use during pregnancy because it may cause fetal harm, based on animal data.

- Category: Safety
- Evidence stage: Evidence stage not applicable
- Certainty: Certainty not assessed
- Applies to: Recipient: Fetal; Population: The developing fetus when a pregnant person takes the medicine, as the label boxed warning describes the risk. The warning is not about the person who takes the medicine.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Fetus during pregnancy; the passage read gives no gestational ages; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)
- Limitations: This claim records the boxed-warning statement named above only. The warning also tells prescribers what to do before and during treatment of people who could become pregnant; that instruction is not repeated here. Other warnings, contraindications and interactions of the label were not recorded, and no pregnancy or lactation guidance is given. Labels change, and openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked: 2026-11-18
- Sources:
  1. Background: openFDA drug label record for Opsumit (macitentan tablets), Actelion Pharmaceuticals US, Inc. label: indications, boxed warning and mechanism (Regulator, edition The openFDA drug label record for set id 1e484a50-55db-4b85-8c57-6cd1b0353abd (manufacturer Actelion Pharmaceuticals US, Inc., application NDA204410), returned on 2026-11-18. The label text is dated 2025-04-11 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used. The combination product Opsynvi (macitentan and tadalafil, NDA218490) was not read.) <https://api.fda.gov/drug/label.json?search=set_id:%221e484a50-55db-4b85-8c57-6cd1b0353abd%22&limit=1>
     Locator: results\[0\].openfda.application\_number\[0\]. Retrieved 2026-11-18T22:01:33Z. Source state: Current. Version fingerprint: d58418de14a806412a924192c2a9f5347b6faa1b49ba412aeffe7e31c1d9eb71.
     How it applies: Application number of the label read, NDA204410.
  2. Background: openFDA drug label record for Opsumit (macitentan tablets), Actelion Pharmaceuticals US, Inc. label: indications, boxed warning and mechanism (Regulator, edition The openFDA drug label record for set id 1e484a50-55db-4b85-8c57-6cd1b0353abd (manufacturer Actelion Pharmaceuticals US, Inc., application NDA204410), returned on 2026-11-18. The label text is dated 2025-04-11 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used. The combination product Opsynvi (macitentan and tadalafil, NDA218490) was not read.) <https://api.fda.gov/drug/label.json?search=set_id:%221e484a50-55db-4b85-8c57-6cd1b0353abd%22&limit=1>
     Locator: results\[0\].effective\_time. Retrieved 2026-11-18T22:01:33Z. Source state: Current. Version fingerprint: d58418de14a806412a924192c2a9f5347b6faa1b49ba412aeffe7e31c1d9eb71.
     How it applies: Effective date of the label text read, 20250411.
  3. Supports: openFDA drug label record for Opsumit (macitentan tablets), Actelion Pharmaceuticals US, Inc. label: indications, boxed warning and mechanism (Regulator, edition The openFDA drug label record for set id 1e484a50-55db-4b85-8c57-6cd1b0353abd (manufacturer Actelion Pharmaceuticals US, Inc., application NDA204410), returned on 2026-11-18. The label text is dated 2025-04-11 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used. The combination product Opsynvi (macitentan and tadalafil, NDA218490) was not read.) <https://api.fda.gov/drug/label.json?search=set_id:%221e484a50-55db-4b85-8c57-6cd1b0353abd%22&limit=1>
     Locator: results\[0\].boxed\_warning\[0\], title. Retrieved 2026-11-18T22:01:33Z. Source state: Current. Version fingerprint: d58418de14a806412a924192c2a9f5347b6faa1b49ba412aeffe7e31c1d9eb71.
     How it applies: Label passage quoted in the research quote table (Q-K29-OPS-LB-06).
  4. Supports: openFDA drug label record for Opsumit (macitentan tablets), Actelion Pharmaceuticals US, Inc. label: indications, boxed warning and mechanism (Regulator, edition The openFDA drug label record for set id 1e484a50-55db-4b85-8c57-6cd1b0353abd (manufacturer Actelion Pharmaceuticals US, Inc., application NDA204410), returned on 2026-11-18. The label text is dated 2025-04-11 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used. The combination product Opsynvi (macitentan and tadalafil, NDA218490) was not read.) <https://api.fda.gov/drug/label.json?search=set_id:%221e484a50-55db-4b85-8c57-6cd1b0353abd%22&limit=1>
     Locator: results\[0\].boxed\_warning\[0\], first paragraph. Retrieved 2026-11-18T22:01:33Z. Source state: Current. Version fingerprint: d58418de14a806412a924192c2a9f5347b6faa1b49ba412aeffe7e31c1d9eb71.
     How it applies: Label passage quoted in the research quote table (Q-K29-OPS-LB-07).

## Context: Adults with pulmonary arterial hypertension, as described in the US label of Opsumit

Recipient: Adult; Population: Adults with pulmonary arterial hypertension (PAH, WHO Group I), as the label states.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Adults, as the label states; Follow-up: Not applicable (label statement)

### The US label of Opsumit (macitentan tablets, Actelion Pharmaceuticals US, Inc., application NDA204410; the version dated 2025-04-11 in openFDA) describes macitentan as an endothelin receptor antagonist. It lists treating pulmonary arterial hypertension (WHO Group I) in adults to reduce the risks of disease progression and hospitalization for pulmonary arterial hypertension.

- Category: Description
- Evidence stage: Evidence stage not applicable
- Certainty: Certainty not assessed
- Applies to: Recipient: Adult; Population: Adults with pulmonary arterial hypertension (PAH, WHO Group I), as the label states.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Adults, as the label states; Follow-up: Not applicable (label statement)
- Limitations: This claim records what one US label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. Contraindications, other warnings, interactions and dosing were not recorded. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked: 2026-11-18
- Sources:
  1. Background: openFDA drug label record for Opsumit (macitentan tablets), Actelion Pharmaceuticals US, Inc. label: indications, boxed warning and mechanism (Regulator, edition The openFDA drug label record for set id 1e484a50-55db-4b85-8c57-6cd1b0353abd (manufacturer Actelion Pharmaceuticals US, Inc., application NDA204410), returned on 2026-11-18. The label text is dated 2025-04-11 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used. The combination product Opsynvi (macitentan and tadalafil, NDA218490) was not read.) <https://api.fda.gov/drug/label.json?search=set_id:%221e484a50-55db-4b85-8c57-6cd1b0353abd%22&limit=1>
     Locator: results\[0\].openfda.application\_number\[0\]. Retrieved 2026-11-18T22:01:33Z. Source state: Current. Version fingerprint: d58418de14a806412a924192c2a9f5347b6faa1b49ba412aeffe7e31c1d9eb71.
     How it applies: Application number of the label read, NDA204410.
  2. Background: openFDA drug label record for Opsumit (macitentan tablets), Actelion Pharmaceuticals US, Inc. label: indications, boxed warning and mechanism (Regulator, edition The openFDA drug label record for set id 1e484a50-55db-4b85-8c57-6cd1b0353abd (manufacturer Actelion Pharmaceuticals US, Inc., application NDA204410), returned on 2026-11-18. The label text is dated 2025-04-11 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used. The combination product Opsynvi (macitentan and tadalafil, NDA218490) was not read.) <https://api.fda.gov/drug/label.json?search=set_id:%221e484a50-55db-4b85-8c57-6cd1b0353abd%22&limit=1>
     Locator: results\[0\].effective\_time. Retrieved 2026-11-18T22:01:33Z. Source state: Current. Version fingerprint: d58418de14a806412a924192c2a9f5347b6faa1b49ba412aeffe7e31c1d9eb71.
     How it applies: Effective date of the label text read, 20250411.
  3. Supports: openFDA drug label record for Opsumit (macitentan tablets), Actelion Pharmaceuticals US, Inc. label: indications, boxed warning and mechanism (Regulator, edition The openFDA drug label record for set id 1e484a50-55db-4b85-8c57-6cd1b0353abd (manufacturer Actelion Pharmaceuticals US, Inc., application NDA204410), returned on 2026-11-18. The label text is dated 2025-04-11 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used. The combination product Opsynvi (macitentan and tadalafil, NDA218490) was not read.) <https://api.fda.gov/drug/label.json?search=set_id:%221e484a50-55db-4b85-8c57-6cd1b0353abd%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\], 1 INDICATIONS AND USAGE. Retrieved 2026-11-18T22:01:33Z. Source state: Current. Version fingerprint: d58418de14a806412a924192c2a9f5347b6faa1b49ba412aeffe7e31c1d9eb71.
     How it applies: Label passage quoted in the research quote table (Q-K29-OPS-LB-04, Q-K29-OPS-LB-05).

## Connected pages

- Macitentan is an endothelin receptor antagonist (FDA established pharmacologic class in RxClass): Endothelin receptor antagonists (`cardio:endothelin-receptor-antagonists`)
- FDA label lists pulmonary arterial hypertension (WHO Group I) in adults, to reduce the risks of disease progression and hospitalization, as an indication: Pulmonary arterial hypertension (`cardio:pulmonary-arterial-hypertension`) [a claim, not a settled fact; see claim `cardio:claim-fda-opsumit-label-indications` and its context]
- Files under this front: Medicines (`cardio:front-medicines`)
- A separate US product combines macitentan and tadalafil, according to its label: Tadalafil (`cardio:tadalafil`)

## Provenance

Content hash: 072e1436ef31f6f703b577ec3e911bbac0dcfb967494906f9cb7d3b0e073c73a
Last substantive edit: 2026-11-18
Evidence last checked: 2026-11-18
